Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Current Prospects for Adrenocortical Carcinoma Pharmacotherapy

Author(s): Hanna Ławnicka*

Volume 18, Issue 1, 2023

Published on: 15 July, 2022

Page: [29 - 37] Pages: 9

DOI: 10.2174/1574892817666220429091643

Price: $65

Abstract

Adrenocortical carcinoma (ACC) is a rare but very aggressive malignancy of the endocrine system with specific biology characterized frequently by hormonal activity and high aggressiveness, resulting usually in locally-invasive or metastatic disease at the time of initial diagnosis. Despite an intense multidirectional search for novel strategies, there has been no satisfactory improvement in the effectiveness of standard therapy currently used in the clinic. ACC diagnosis usually means poor prognosis. Thus, the necessity to identify and implement novel and more effective treatment of ACC in clinical management remains constantly an ambitious challenge.

The review briefly summarizes the current management of adrenocortical carcinoma and focuses mainly on novel prospects for ACC pharmacotherapy, including targeted therapies, immunotherapy and checkpoint inhibitors, theranostics, and at last, the individualized molecular approach based on the exact identification of specific genetic profile of ACC cells using next-generation sequencing methods as the next-generation perspective for precisely personalized therapy.

Keywords: Adrenocortical carcinoma, targeted therapy, immunotherapy, personalized molecular therapy, clinical trials, phar-macotherapy.

« Previous Next »
[1]
Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31(11): 1476-90.
[http://dx.doi.org/10.1016/j.annonc.2020.08.2099] [PMID: 32861807]
[2]
Fassnacht M, Dekkers OM, Else T, et al. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 2018; 179(4): G1-G46.
[http://dx.doi.org/10.1530/EJE-18-0608] [PMID: 30299884]
[3]
Souteiro P, Donato S, Costa C, et al. Diagnosis, treatment, and survival analysis of adrenocortical carcinomas: A multicentric study. Hormones (Athens) 2020; 19(2): 197-203.
[http://dx.doi.org/10.1007/s42000-019-00161-1] [PMID: 31823340]
[4]
Kiesewetter B, Riss P, Scheuba C, et al. Management of adrenocortical carcinoma: Are we making progress? Ther Adv Med Oncol 2021; 13: 17588359211038409.
[http://dx.doi.org/10.1177/17588359211038409] [PMID: 34484430]
[5]
Jasim S, Habra MA. Management of adrenocortical carcinoma. Curr Oncol Rep 2019; 21(3): 20.
[http://dx.doi.org/10.1007/s11912-019-0773-7] [PMID: 30798468]
[6]
Shariq OA, McKenzie TJ. Adrenocortical carcinoma: Current state of the art, ongoing controversies, and future directions in diagnosis and treatment. Ther Adv Chronic Dis 2021; 12: 20406223211033103.
[http://dx.doi.org/10.1177/20406223211033103] [PMID: 34349894]
[7]
Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366(23): 2189-97.
[http://dx.doi.org/10.1056/NEJMoa1200966] [PMID: 22551107]
[8]
Uchihara M, Tanioka M, Kojima Y, et al. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: A single institute experience. Int J Clin Oncol 2021; 26(12): 2275-81.
[http://dx.doi.org/10.1007/s10147-021-02021-8] [PMID: 34468885]
[9]
Altieri B, Ronchi CL, Kroiss M, Fassnacht M. Next-generation therapies for adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2020; 34(3): 101434.
[http://dx.doi.org/10.1016/j.beem.2020.101434] [PMID: 32622829]
[10]
Konda B, Kirschner LS. Novel targeted therapies in adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes 2016; 23(3): 233-41.
[http://dx.doi.org/10.1097/MED.0000000000000247] [PMID: 27119750]
[11]
Paragliola RM, Corsello A, Locantore P, Papi G, Pontecorvi A, Corsello SM. Medical approaches in adrenocortical carcinoma. Biomedicines 2020; 8(12): 551.
[http://dx.doi.org/10.3390/biomedicines8120551] [PMID: 33260476]
[12]
Papadopoulos KP, El-Rayes BF, Tolcher AW, et al. A phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br J Cancer 2017; 117(11): 1592-9.
[http://dx.doi.org/10.1038/bjc.2017.330] [PMID: 28972963]
[13]
Fassnacht M, Berruti A, Baudin E, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study. Lancet Oncol 2015; 16(4): 426-35.
[http://dx.doi.org/10.1016/S1470-2045(15)70081-1] [PMID: 25795408]
[14]
Kroiss M, Megerle F, Kurlbaum M, et al. Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. J Clin Endocrinol Metab 2020; 105(5): 1461-8.
[http://dx.doi.org/10.1210/clinem/dgz318] [PMID: 31900481]
[15]
Smith DC, Kroiss M, Kebebew E, et al. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Invest New Drugs 2020; 38(5): 1421-9.
[http://dx.doi.org/10.1007/s10637-020-00899-1] [PMID: 31984451]
[16]
Fragni M, Palma Lopez LP, Rossini E, et al. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures Mol Cell Endocrinol 2019; 498: 110585.
[http://dx.doi.org/10.1016/j.mce.2019.110585] [PMID: 31536779]
[17]
Habra MA, Stephen B, Campbell M, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 2019; 7(1): 253.
[http://dx.doi.org/10.1186/s40425-019-0722-x] [PMID: 31533818]
[18]
Le Tourneau C, Hoimes C, Zarwan C, et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: Phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer 2018; 6(1): 111.
[http://dx.doi.org/10.1186/s40425-018-0424-9] [PMID: 30348224]
[19]
Raj N, Zheng Y, Kelly V, et al. PD-1 blockade in advanced adrenocortical carcinoma. J Clin Oncol 2020; 38(1): 71-80.
[http://dx.doi.org/10.1200/JCO.19.01586] [PMID: 31644329]
[20]
Brabo EP, Moraes AB, Neto LV. The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: Review of literature. J Endocrinol Invest 2020; 43(11): 1531-42.
[http://dx.doi.org/10.1007/s40618-020-01306-5] [PMID: 32468513]
[21]
Miller KC, Chintakuntlawar AV, Hilger C, et al. Salvage therapy with multikinase inhibitors and immunotherapy in advanced adrenal cortical carcinoma. J Endocr Soc 2020; 4(7): bvaa069.
[http://dx.doi.org/10.1210/jendso/bvaa069]
[22]
Bedrose S, Miller KC, Altameemi L, et al. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J Immunother Cancer 2020; 8(2): e001009.
[http://dx.doi.org/10.1136/jitc-2020-001009] [PMID: 32737143]
[23]
Cosentini D, Grisanti S, Dalla Volta A, et al. Immunotherapy failure in adrenocortical cancer: Where next? Endocr Connect 2018; 7(12): E5-8.
[http://dx.doi.org/10.1530/EC-18-0398] [PMID: 30400026]
[24]
Georgantzoglou N, Kokkali S, Tsourouflis G, Theocharis S. Tumor microenvironment in adrenocortical carcinoma: Barrier to immunotherapy success? Cancers (Basel) 2021; 13(8): 1798.
[http://dx.doi.org/10.3390/cancers13081798] [PMID: 33918733]
[25]
Pegna GJ, Roper N, Kaplan RN, et al. The immunotherapy landscape in adrenocortical cancer. Cancers (Basel) 2021; 13(11): 2660.
[http://dx.doi.org/10.3390/cancers13112660] [PMID: 34071333]
[26]
Hahner S, Kreissl MC, Fassnacht M, et al. [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab 2012; 97(3): 914-22.
[http://dx.doi.org/10.1210/jc.2011-2765] [PMID: 22170726]
[27]
Grisanti S, Filice A, Basile V, et al. Treatment with 90Y/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors. J Clin Endocrinol Metab 2020; 105(3): dgz091.
[http://dx.doi.org/10.1210/clinem/dgz091] [PMID: 31633759]
[28]
Chifu I, Heinze B, Fuss CT, et al. Impact of the chemokine receptors CXCR4 and CXCR7 on clinical outcome in adrenocortical carcinoma. Front Endocrinol (Lausanne) 2020; 11: 597878.
[http://dx.doi.org/10.3389/fendo.2020.597878] [PMID: 33281749]
[29]
Bluemel C, Hahner S, Heinze B, et al. Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients. Clin Nucl Med 2017; 42(1): e29-34.
[http://dx.doi.org/10.1097/RLU.0000000000001435] [PMID: 27819856]
[30]
Crona J, Beuschlein F. Adrenocortical carcinoma - towards genomics guided clinical care. Nat Rev Endocrinol 2019; 15(9): 548-60.
[http://dx.doi.org/10.1038/s41574-019-0221-7] [PMID: 31147626]
[31]
Alyateem G, Nilubol N. Current status and future targeted therapy in adrenocortical cancer. Front Endocrinol (Lausanne) 2021; 12: 613248.
[http://dx.doi.org/10.3389/fendo.2021.613248] [PMID: 33732213]
[32]
Nilubol N, Boufraqech M, Zhang L, et al. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response. Oncotarget 2018; 9(68): 33030-42.
[http://dx.doi.org/10.18632/oncotarget.26050] [PMID: 30250647]
[33]
Zhu Y, Wang M, Zhao X, et al. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma. Oncotarget 2017; 8(14): 22825-34.
[http://dx.doi.org/10.18632/oncotarget.15221] [PMID: 28423559]
[34]
Satoh K, Zhang L, Zhang Y, et al. Identification of niclosamide as a novel anticancer agent for adrenocortical carcinoma. Clin Cancer Res 2016; 22(14): 3458-66.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2256] [PMID: 26873959]
[35]
Pereira SS, Monteiro MP, Costa MM, et al. MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors. J Cell Biochem 2019; 120(1): 894-906.
[http://dx.doi.org/10.1002/jcb.27451] [PMID: 30256438]
[36]
Hui W, Liu S, Zheng J, Fang Z, Ding Q, Feng C. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation. Cancer Med 2018; 7(4): 1440-9.
[http://dx.doi.org/10.1002/cam4.1431] [PMID: 29532999]
[37]
Bussey KJ, Bapat A, Linnehan C, et al. Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma. Clin Transl Med 2016; 5(1): 1.
[http://dx.doi.org/10.1186/s40169-015-0080-3] [PMID: 26754547]
[38]
Hasanovic A, Ruggiero C, Jung S, et al. Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo. Int J Cancer 2018; 143(1): 199-211.
[http://dx.doi.org/10.1002/ijc.31296] [PMID: 29411361]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy